DryPod is built using a proprietary lamination-based approach, enabling consistent performance across all standard blister-forming technologies
ACG announced the launch of DryPod, a next-generation desiccant-based cold-form laminate engineered to protect highly moisture-sensitive drug molecules.
DryPod is built using a proprietary lamination-based approach, enabling consistent performance across all standard blister-forming technologies. This eliminates the need for specialised retrofits or process changes and gives manufacturers complete flexibility to run DryPod on their existing blister lines. The laminate can also be sealed with any PE-sealable lidding foil, reducing procurement dependencies and ensuring supply-chain agility across global operations. A significant differentiator for DryPod is its patent-clean design.
“DryPod is built for the realities of modern pharmaceutical manufacturing,” said Dr Akbar Ali, General Manager and Head of Development and Technologies, ACG. “Manufacturers working with moisture-sensitive molecules have faced years of constraints due to rigid technologies and supply limitations. DryPod directly addresses these challenges, empowering innovators to bring critical therapies to market more efficiently and reliably.”
